Arab Israeli Conflict
Hi Tech News
Mylan rejected Teva's $41 billion bid earlier this week.
Acquisition would create leading company with potential to transform global market for generics.
Teva sought stay of lower court ruling that favored developers of generic versions of its top selling multiple sclerosis drug.
CEO of generics giant says move not due to financial distress; Teva employs 7500 people in Israel.
By GALI WEINREB, SHAY NIV AND ADI BEN-ISRAEL / GLO
Judge Ariella Gilzer-Kats: We were shown a dismal picture, which is inappropriate for a company in a civilized country.
By CHEN MA'ANIT
Labor chairwoman demands discussion in Knesset Finance Committee after Teva Pharmaceuticals reportedly paid a .3% tax rate.
By NIV ELIS
Company hopes generic versions of MS drug will be delayed by clinical trials.
By SHIRI HABIB-VALDHORN
Expert: Company to report net profit of $4.74 billion this year.
By NADAV NEUMAN
If passed, VAT will rise one percentage point to 17%; Finance C'mtee reject Gafni proposal to raise corporate tax; Treasury General says "only a marginal increase."
By NADAV SHEMER
Teva developing more than 70 innovative drugs
By GLOBES CORRESPONDENT
For a long time, market rumors have persisted that Yanai was on his way out.
By SHIRI HABIB-VALDHORN/GLOBES
The appointment of Dr. Jeremy Levin to CEO of Teva Pharmaceuticals is the first time a foreigner has headed the company.
By STEVE LINDE
Yanai will be replaced by Dr. Jeremy Levin, a former senior executive at Bristol-Myers Squibb.
Please insert a valid email address